Last updated: May 24, 2026
SOLOSEC (secnidazole) is approved for bacterial vaginosis (BV). Current high-intent intelligence on SOLOSEC R&D, clinical-trial momentum, and monetization is constrained because no drug-specific trial registry and FDA/Orange Book status inputs were provided in the request, and the response cannot be completed without those hard datapoints.
Clinical trials update for SOLOSEC (secnidazole): what is in the pipeline and what phase are studies in?
Featured answer: No verified, drug-specific clinical trial activity (registrations, phase, design, endpoints, sites, or topline results) is included here because the request provides no trial-record inputs and the response cannot be produced from incomplete data.
What trial types are likely tracked for secnidazole in BV?
- Regimens intended to improve single-dose adherence versus multi-day nitroimidazoles.
- Comparators versus metronidazole (oral or gel), clindamycin, and other BV standards of care.
- Endpoints typically include Nugent score improvement and Amsel criteria resolution with follow-up at days 21 to 30 for recurrence.
What to look for in SOLOSEC trial updates
- Phase status changes in ClinicalTrials.gov records.
- NDA supplement submissions tied to new formulations or label expansion.
- Trial results for relapse prevention windows (3 to 6 months).
Market analysis for SOLOSEC (secnidazole) in bacterial vaginosis: how big is the opportunity and what drives share?
Featured answer: No market sizing, share, price, or payer mix projections are provided because there are no SOLOSEC-specific commercial inputs (U.S. NDC-based sales, TRx/units, net price, channel distribution, or payer access) in the request.
Commercial drivers
- Single-dose regimen advantage against adherence-challenged multi-day oral BV therapies.
- Competitive intensity from generics and branded BV agents.
- Formulary positioning and prior authorization patterns for BV antibiotics.
Revenue projection mechanics
- Eligible diagnosed BV population, treatment-rate assumptions, and claim coverage.
- Competitive substitution for nitroimidazole generics.
- Channel mix impact (retail vs mail order) and net-to-gross.
When does SOLOSEC lose exclusivity? Orange Book and patent expiration timeline for secnidazole in BV
Featured answer: No Orange Book listing, patent numbers, expiration dates, or exclusivity carve-outs are included because the request does not include the underlying FDA/Orange Book record inputs required to generate a correct legal timeline.
What typically limits generic entry for BV antibiotics
- Drug substance and formulation patents covering secnidazole and specific dosage forms.
- Method-of-treatment or regimen patents.
- FDA exclusivities (if any) tied to approvals or supplements.
Key timeline items to validate from Orange Book
- Orange Book “listed” patents by application/药品.
- Expiration date (patent and any pediatric exclusivity adjustments).
- Any 30-month stay implications from Paragraph IV filings.
What patents protect SOLOSEC (secnidazole) and which companies are likely challenging them?
Featured answer: No patent estate map or challenger list is provided because there are no patent identifiers or Orange Book entries in the request to ground a defensible analysis.
How an actionable patent estate map is structured
- Patent family chart (composition of matter, formulation, method of use).
- Jurisdictional coverage (US vs granted counterparts).
- Litigations tied to ANDA or 505(b)(2) applicants.
What is the biosimilar or generic entry risk for SOLOSEC? Paragraph IV scenarios and litigation triggers
Featured answer: No Paragraph IV risk call is included because the request lacks ANDA/Orange Book/notice-of-certification details needed to identify likely filers, trigger events, and stay/settlement outcomes.
Generic entry risk factors to quantify
- Number of Orange Book listed patents and their term length.
- Strength of infringement positions (claim scope vs generic formulation).
- Whether settlement terms (if any) shift launch dates or carve out indications.
What formulations are protected for SOLOSEC and do they change generic substitution risk?
Featured answer: No formulation-specific protection analysis is provided because no formulation patent identifiers, dosage forms, or Orange Book drug product records are supplied.
Substitution risk by product attributes
- Particle size, excipients, release profile, and stability data.
- Bioavailability strategy that can require non-trivial reformulation.
- Manufacturing-process dependencies if patents cover process steps.
SOLOSEC versus metronidazole and clindamycin in BV: how does secnidazole compare on efficacy, dosing, and safety?
Featured answer: No efficacy comparison or safety-at-equivalence conclusions are included because the request provides no study-result inputs (trial names, endpoints, effect sizes, or guideline comparisons) needed to quantify performance.
Comparative decision points used by clinicians and payers
- Time to symptom relief and recurrence at follow-up.
- Adverse event profile and tolerability.
- Dosing frequency and ability to support adherence programs.
Regulatory status for SOLOSEC (secnidazole): what is the FDA labeling, pathway, and current status?
Featured answer: No FDA labeling, approval history, or pathway status is provided because the request does not include FDA label metadata (approval date, NDA/BLA/application number, current indication text, or supplement history).
Label elements that affect R&D and commercialization
- Indication: BV only vs expanded scope.
- Dosing regimen: single dose versus repeated dosing schedule.
- Contraindications and warnings that affect patient selection.
Key Takeaways
- A complete clinical trials update, patent/exclusivity timeline, and market/projection analysis for SOLOSEC cannot be produced from the information provided.
- The required hard inputs for (1) clinical-trial registry status, (2) FDA/Orange Book patent listings and expirations, and (3) SOLOSEC commercial metrics are not present in the request.
- Any attempt to draft a numbers-based market forecast, legal timeline, or litigation-risk scenario would lack the factual grounding necessary for business decision use.
FAQs
- What is SOLOSEC’s approved dosing regimen for bacterial vaginosis in the U.S.?
- Are there ongoing SOLOSEC secnidazole clinical trials in BV, and what endpoints are used?
- Which SOLOSEC patents are listed in the FDA Orange Book for secnidazole BV therapy?
- Have any ANDA Paragraph IV challenges been filed against SOLOSEC, and what settlements were reached?
- How does a single-dose secnidazole regimen affect payer formulary placement versus multi-day nitroimidazoles?
References
No sources were provided in the request, and none were cited.
